Morgan Stanley Initiates Coverage On Abivax with Equal-Weight Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has initiated coverage on Abivax with an Equal-Weight rating and set a price target of $15. Abivax is listed on NASDAQ under the ticker ABVX.

November 14, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley initiated coverage on Abivax with an Equal-Weight rating and a price target of $15, which could influence investors' perception of the stock.
The initiation of coverage by Morgan Stanley with an Equal-Weight rating suggests a neutral outlook on the stock, indicating that the stock is adequately valued at its current price. The announcement of a price target provides a benchmark for investors but does not necessarily imply a significant short-term price movement, hence the neutral score. The relevance is high as the news is directly about Abivax, and the importance is significant as analyst ratings can impact investor sentiment. The confidence level is high due to the credibility of Morgan Stanley as a financial institution.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100